Current Environment: Production

Medical Services

Specialties

Programs & Services

Languages

  • English

Education

Graduate School

Case Western Reserve University

Cleveland, OH

Medical School

Case Western Reserve University

Cleveland, OH

Residency

Boston Combined Residency Program (BCRP)

Boston, MA

Fellowship

Dana-Farber Cancer Institute

Boston, MA

Certifications

  • American Board of Pediatrics (General)

Professional History

Dr. Morrow received his bachelor’s degree in biology with highest honors at Pennsylvania State University. He attended medical school at Case Western Reserve University, where he was selected as an HHMI-NIH Research Scholar. During this fellowship James worked in the pediatric oncology branch at the National Cancer Institute (NCI), studying the molecular mechanisms of solid tumor metastasis.

James went on to complete a PhD, splitting research time between Case Western and NCI. His research showed that gene enhancer dysregulation is a key driver of osteosarcoma metastasis. James completed his pediatric residency in the Boston Combined Residency Program at Boston Children’s Hospital. He then completed his Pediatric Hematology/Oncology Fellowship at Dana-Farber Cancer Institute.

James is currently an attending physician treating children and adolescents with cancer and hematologic diseases. He is also completing research in the lab of Bradley Bernstein at DFCI, studying the developmental origins and evolution of pediatric solid tumors.

Publications

  1. Genomic analysis reveals germline and somatic PDGFRB variants with clinical implications in familial infantile myofibromatosis. Pediatr Blood Cancer. 2023 06; 70(6):e30262. View Abstract

  2. Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma. J Clin Invest. 2019 10 01; 129(10):4377-4392. View Abstract

  3. Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med. 2018 Apr 10; 24(4):525. View Abstract

  4. Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. Nat Med. 2018 02; 24(2):176-185. View Abstract

  5. Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature. 2018 01 04; 553(7686):101-105. View Abstract

  6. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. 2017 07 20; 547(7663):355-359. View Abstract

  7. Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nat Commun. 2017 02 07; 8:14400. View Abstract

  8. Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression. Neoplasia. 2016 11; 18(11):699-710. View Abstract

  9. mTOR Inhibition Mitigates Enhanced mRNA Translation Associated with the Metastatic Phenotype of Osteosarcoma Cells In Vivo. Clin Cancer Res. 2016 Dec 15; 22(24):6129-6141. View Abstract

  10. Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. Crit Rev Oncog. 2015; 20(3-4):173-97. View Abstract

  11. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res. 2015 Jan; 3(1):37-47. View Abstract

  12. RET mutation and expression in small-cell lung cancer. J Thorac Oncol. 2014 Sep; 9(9):1316-23. View Abstract
BESbswy